Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Trizell Ltd. announces Phase 3 pivotal study of interferon alfa-2b gene therapy in malignant pleural mesothelioma

firstwordpharmaMarch 21, 2019

Tag: Trizell , interferon alfa-2b , pleural mesothelioma

PharmaSources Customer Service